New malaria drug could be a game changer
Swiss Malaria Group (SMG) Novartis and Medicines for Malaria Venture launch a patient trial in Africa for KAF156 , a novel compound against multidrug resistant malaria:
The compound has the potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.
KAF156 is the first compound from the imidazolopiperazines, a novel class of antimalarials, to enter phase IIb combination studies.
Clinical trial have started early August in adults with malaria and is planned to expand to adolescents and children in a total of nine countries in Africa and Asia.